November 17, 2018
SPT Staff
Pembrolizumab (Keytruda) is indicated for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib.


Kristen Coppock, MA, Editor
Udenyca (pegfilgrastim-cbqv) is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. 
Jennifer Barrett, Associate Editor
Tildrakizumab-asmn (Ilumya), an injectable interleukin-23 (IL-23) inhibitor, was approved by the FDA in March for adults with plaque psoriasis who are candidates for systemic therapy or phototherapy. 
Kristen Coppock, MA, Editor
Dupixent approved as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older.
Jennifer Barrett, Associate Editor
Talazoparib is indicated for patients with known deleterious or suspected deleterious gBRCA-mutated breast cancer.
Cecilia Pessoa Gingerich
Patients with multiple sclerosis who began treatment with ocrelizumab 2 years earlier had significant reductions in 24-week confirmed disability progression compared to patients who switched from interferon beta-1a.
About the Specialty Pharmacy Times Industry Guide

The Specialty Pharmacy Times Industry Guide includes comprehensive editorial content relative to all specialty pharmacy stakeholders. Content includes information relative to market trends, commercialization, distribution, order to cash, HUB Services, managed care strategies and DIR fees. The guide also includes profiles, and a complete list of stakeholders along the patient journey: specialty pharmacies, wholesaler distributors, manufacturers, support services, group purchasing, and trade associations.

Sign Up for the Industry Guide Newsletter

Copyright © 2006-2018 Pharmacy & Healthcare Communications, LLC
All Rights Reserved

About Us